IRX4204 Induces Senescence and Cell Death in HER2-positive Breast Cancer and Synergizes with Anti-HER2 Therapy
CONCLUSIONS: These findings identify HER2 as a biomarker for IRX4204 treatment response and demonstrate a novel use of RXR agonists to synergize with current anti-HER2 therapies. Furthermore, our results suggest that RXR agonists can be useful for the treatment of anti-HER2 resistant and metastatic HER2-positive breast cancer.PMID:38578278 | DOI:10.1158/1078-0432.CCR-23-3839 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 5, 2024 Category: Cancer & Oncology Authors: Cassandra L Moyer Amanda Lanier Jing Qian Darian Coleman Jamal Hill Vidyasagar Vuligonda Martin E Sanders Abhijit Mazumdar Powel H Brown Source Type: research
Population Pharmacokinetics of Sacituzumab Govitecan in Patients with Metastatic Triple-Negative Breast Cancer and Other Solid Tumors
CONCLUSIONS: These analyses support the approved SG dosing regimen of 10 mg/kg as intravenous infusion on days 1 and 8 of 21-day cycles and did not identify a need for dose adjustment based on evaluated covariates or disease characteristics.PMID:38578394 | DOI:10.1007/s40262-024-01366-3 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 5, 2024 Category: Cancer & Oncology Authors: Abhishek G Sathe Indrajeet Singh Pratap Singh Paul M Diderichsen Xiaohui Wang Peter Chang Atiya Taqui See Phan Sandhya Girish Ahmed A Othman Source Type: research
Hypertension as predictive factor for bevacizumab-containing first-line therapy in metastatic breast and colorectal cancer in BRECOL (GEICAM/2011-04) study
CONCLUSIONS: Neither the frequency of AHT nor the increase of BP levels were predictive of efficacy in MBC and mCRC patients treated with bevacizumab-containing chemotherapy.CLINICAL TRIAL REGISTRY: ClinicalTrials.gov Identifier: NCT01733628.PMID:38578537 | DOI:10.1007/s12094-024-03411-w (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 5, 2024 Category: Cancer & Oncology Authors: Álvaro Rodríguez-Lescure Javier Gallego Pilar Garcia-Alfonso Bartomeu Massuti Ra úl Márquez Lourdes Calvo Pedro S ánchez-Rovira Antonio Ant ón Jos é Ignacio Chacón Eva Ciruelos Jose Juan Ponce Ana Santaballa Manuel Valladares-Ayerbes Mar ía Rosar Source Type: research
Effectiveness of G-CSF in chemotherapy for digestive system tumors: a systematic review of the Clinical Practice Guidelines for the Use of G-CSF 2022 delineated by the Japan Society of Clinical Oncology
CONCLUSION: The use of G-CSF for primary prophylaxis in chemotherapy for colorectal cancer is inappropriate.PMID:38578596 | DOI:10.1007/s10147-024-02502-6 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 5, 2024 Category: Cancer & Oncology Authors: Mamoru Ito Yuta Okumura Kenta Nio Eishi Baba Yukinori Ozaki Hiroshi Nishio Eiki Ichihara Yuji Miura Makoto Endo Shingo Yano Dai Maruyama Tetsuhiro Yoshinami Nobuyuki Susumu Munetaka Takekuma Takashi Motohashi Nobuaki Ochi Toshio Kubo Keita Uchino Takahiro Source Type: research
Targeting Breast Cancer Using 177Lu-Labeled Trastuzumab and Trastuzumab Fragment: First-in-Human Clinical Experience
CONCLUSIONS: 177Lu-DOTAGA-Fab and trastuzumab are suitable for targeting the HER2 receptors.PMID:38579266 | DOI:10.1097/RLU.0000000000005208 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 5, 2024 Category: Cancer & Oncology Authors: Yogesh Rathore Tamanna Lakhanpal Sudipta Chakraborty Rubel Chakravarty B R Mittal R N Santhosh Irrinki Ishita Laroiya Komalpreet Kaur Jaya Shukla Source Type: research
PARP Inhibitor for Neoadjuvant Therapy in HER2-Negative Breast Cancer: A Systematic Review and Meta-Analysis of Efficacy and Safety
Clin Breast Cancer. 2024 Mar 2:S1526-8209(24)00059-4. doi: 10.1016/j.clbc.2024.02.020. Online ahead of print.ABSTRACTPoly-ADP ribose polymerase inhibitor (PARPi) is approved for HER2-negative advanced breast cancer with BRCA1/2 mutation. In recent years, many studies have explored the application of PARPi in neoadjuvant therapy, but failed to reach a unified conclusion. PubMed, Clinicaltrials.gov, Cochrane CENTRAL, Embase, and key oncological meetings for trials were searched for studies reporting neoadjuvant regimens with PARPi in HER2-negative breast cancer. Pathological complete response (pCR), residual cancer burden (R...
Source: Clinical Breast Cancer - April 5, 2024 Category: Cancer & Oncology Authors: Xiaomeng Jia Kainan Wang Qiping Zhuo Zuowei Zhao Man Li Source Type: research
Nomogram Based on US and Clinicopathologic Characteristics: Axillary Nodal Evaluation Following Neoadjuvant Chemotherapy in Patients With Node-Positive Breast Cancer
CONCLUSION: Nomogram incorporating routine clinicopathologic and US characteristics can predict nodal pCR and represents a tool to aid in treatment decisions for the axilla after NAC in breast cancer patients.PMID:38580573 | DOI:10.1016/j.clbc.2024.03.005 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 5, 2024 Category: Cancer & Oncology Authors: Jia-Xin Huang Yi-Jie Chen Xue-Yan Wang Jia-Hui Huang Ke-Hong Gan Li-Na Tang Xiao-Qing Pei Source Type: research
Ferroptosis biomarkers predict tumor mutation burden's impact on prognosis in HER2-positive breast cancer
CONCLUSION: Our model helps guide the prognosis of HER2+ breast cancer patients, and its combination with the TMB can aid in more accurate assessment of patient prognosis and provide new ideas for further diagnosis and treatment.PMID:38576597 | PMC:PMC10989258 | DOI:10.5306/wjco.v15.i3.391 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 5, 2024 Category: Cancer & Oncology Authors: Jin-Yu Shi Xin Che Rui Wen Si-Jia Hou Yu-Jia Xi Yi-Qian Feng Ling-Xiao Wang Shi-Jia Liu Wen-Hao Lv Ya-Fen Zhang Source Type: research
Biochemical Significance of miR-155 and miR-375 as Diagnostic Biomarkers and Their Correlation with the NF-kappabeta/TNF-alpha Axis in Breast Cancer
This study aimed to investigate serum expression folds of miR-155 and miR-375 and their correlations with NF-κβ and TNF-α in breast cancer patients. The current study was conducted on 183 unrelated female participants. Serum levels of free T3 and T4, as well as expression folds of miR-155 and miR-375, were significantly higher in patients with fibroadenoma and breast cancer, despite TSH being significantly lower. Additionally, the signaling of TNF-alpha and NF-κβ were found to be significantly upregulated in the serum of patients with breast cancer. Up-regulation of miR-155 and miR-375 expression may be diagnostic bio...
Source: Clinical Breast Cancer - April 5, 2024 Category: Cancer & Oncology Authors: Sahar A Abdel-Samed Walaa G Hozyen Saeed M Shaaban Nabil A Hasona Source Type: research
Circulating miRNA-21 Levels in Breast Cancer Patients Before and After Chemotherapy and Its Association with Clinical Improvement
Indian J Clin Biochem. 2024 Apr;39(2):214-220. doi: 10.1007/s12291-023-01129-0. Epub 2023 Mar 30.ABSTRACTBreast cancer is the most frequent type of cancer in women, many patients experience recurrences and metastasis. miR-21 (microRNA-21) as biomarker is under investigation for breast cancer. At present, there is very limited information available regarding effect of chemotherapy on miR-21 expression in breast cancer and its correlation with the clinical improvement. Hence, this study was planned to evaluate the effect of chemotherapy on miR-21 in metastatic breast cancer and its relationship with the clinical outcome. Fem...
Source: Clinical Breast Cancer - April 5, 2024 Category: Cancer & Oncology Authors: Sanchi Sukhija Purvi Purohit Puneet Pareek Pawan Kumar Garg Jeewan Ram Vishnoi Poonam Abhay Elhence Shobhan Babu Varthya Praveen Sharma Sneha Ambwani Jaykaran Charan Source Type: research
Prognostic impact of tumor-associated neutrophils in breast cancer
CONCLUSION: The present results suggest that a higher density of TANs correlates with unfavorable prognostic factors in breast cancer. Further research on clinicopathological and genetic factors associated with TANs in breast cancer is needed.PMID:38577697 | PMC:PMC10988089 | DOI:10.62347/JQDQ1527 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 5, 2024 Category: Cancer & Oncology Authors: Akinari Kakumoto Tsengelmaa Jamiyan Hajime Kuroda Oi Harada Tomomi Yamaguchi-Isochi Shogo Baba Yasutaka Kato Hiroshi Nishihara Hiroyuki Kawami Source Type: research
Proteomic and metabolomic characterization of bone, liver, and lung metastases in plasma of breast cancer patients
CONCLUSIONS: For bone metastasis, biomarkers such as leucyl-tryptophan, LysoPC(P-16:0/0:0), FN1, and HSPG2 have been validated. dUDP, LPE(18:1/0:0), and aspartylphenylalanine have been confirmed for liver metastasis. For lung metastasis, dUDP, testosterone sulfate, and PE(14:0/20:5) have been established.PMID:38571380 | DOI:10.1002/prca.202300136 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 4, 2024 Category: Cancer & Oncology Authors: Hui Ye Xiabo Shen Yaohan Li Weibin Zou Syed Shams Ul Hassan Yue Feng Xiaojia Wang Jingkui Tian Xiying Shao Yi Tao Wei Zhu Source Type: research
Case report: Emerging BRCA mutation confers benefit from olaparib after chemotherapy intolerance in advanced triple-negative breast cancer
Clin Case Rep. 2024 Apr 3;12(4):e8680. doi: 10.1002/ccr3.8680. eCollection 2024 Apr.ABSTRACTKEY CLINICAL MESSAGE: In a patient with metastatic breast cancer, an acquired BRCA mutation in the BRCA gene was detected, resulting in benefits from olaparib treatment. This underscores the importance of ongoing genetic phenotype testing after paclitaxel chemotherapy.ABSTRACT: Triple-negative breast cancer (TNBC) is associated with a poor prognosis and elevated mortality risk. BRCA mutations are commonly regarded as prevalent mutations in TNBC patients, strongly associated with congenital familial heredity. Dynamic changes in mutat...
Source: Clinical Breast Cancer - April 4, 2024 Category: Cancer & Oncology Authors: Xia-Bo Shen Jia-Yi Wu Jia-Ying Li Xi-Ying Shao Xiao-Jia Wang Source Type: research
Engineering exosomes to reshape the immune microenvironment in breast cancer: Molecular insights and therapeutic opportunities
CONCLUSIONS: By elucidating the contribution of engineered exosomes to breast cancer immunomodulation, this review underscores the transformative potential of this emerging field for improving breast cancer therapy.HIGHLIGHTS: Surface modification of exosomes can improve the targeting specificity. The engineered exosome-loaded immunomodulatory cargo regulates the tumour immune microenvironment. Engineered exosomes are involved in the immune regulation of breast cancer.PMID:38572668 | PMC:PMC10993163 | DOI:10.1002/ctm2.1645 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 4, 2024 Category: Cancer & Oncology Authors: Jilong Cao Gang Lv Fang Wei Source Type: research
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
This article presents global cancer statistics by world region for the year 2022 based on updated estimates from the International Agency for Research on Cancer (IARC). There were close to 20 million new cases of cancer in the year 2022 (including nonmelanoma skin cancers [NMSCs]) alongside 9.7 million deaths from cancer (including NMSC). The estimates suggest that approximately one in five men or women develop cancer in a lifetime, whereas around one in nine men and one in 12 women die from it. Lung cancer was the most frequently diagnosed cancer in 2022, responsible for almost 2.5 million new cases, or one in eight cance...
Source: Clinical Breast Cancer - April 4, 2024 Category: Cancer & Oncology Authors: Freddie Bray Mathieu Laversanne Hyuna Sung Jacques Ferlay Rebecca L Siegel Isabelle Soerjomataram Ahmedin Jemal Source Type: research
